Pending Consolidation, Pradaxa Suits Increase
Last week, lawyers presented arguments regarding the consolidation of federal Pradaxa lawsuits before a panel of judges. Following significant press about deaths and injuries from Pradaxa internal bleeding, Pradaxa dangerous drug lawsuits continue to be filed. At this point, records show roughly 50 Pradaxa complaints spread across more than twenty U.S. District Courts.
All recent Pradaxa lawsuits are based on similar claims that Boehringer Ingelheim did not sufficiently research Pradaxa side effects, nor did they adequately warn patients and the medical community about the significant risks linked to this relatively new blood thinner.
Pradaxa (dabigitran) is an anticoagulant released by Boehringer Ingelheim in October 2010. In the short time since Pradaxa was introduced into the market, it has become one of a few medications that top the FDA’s list of adverse event reports.
Pradaxa has been promoted as a superior alternative to Coumadin (warfarin) to prevent blood clots and strokes in patients who have atrial fibrillation. While Pradaxa requires less patient monitoring than warfarin, warfarin bleeding can be stopped with a dose of Vitamin K and there is no reversal agent for Pradaxa internal bleeding. Because of this, thousands of Americans have suffered uncontrollable bleeding after taking Pradaxa, leading to severe injury or even death.
In a 2012 report from the Institute for Safe Medication Practices (ISMP), researchers disclose that 2,367 instances of Pradaxa hemorrhaging and 542 deaths related to Pradaxa were reported in 2011 alone.
The motion to consolidate federal Pradaxa lawsuits was filed by Vera Lee Sellers in May 2012. Sellers asked that the cases be brought before Judge David R. Herndon in the Southern District of Illinois as part of a multidistrict litigation (MDL). When Sellers filed the motion, there were 21 Pradaxa suits in progress in 12 districts, with the majority of those lawsuits brought in the Southern District of Illinois.
Boehringer Ingelheim responded to the request for an MDL in June, agreeing to a centralization of the lawsuits but suggesting a different location for the trial proceedings. The company asks that the suits be moved to the U.S. District Court for the District of Connecticut, which is near the drug maker’s headquarters.
On July 20, Boehringer Ingelheim disclosed that there are 47 cases pending in 21 different federal district courts, with more than one-half of those cases in the Southern District of Illinois. Boehringer Ingelheim suggested that plaintiffs’ lawyers intentionally filed a number of cases in Illinois in time to correspond with the MDL request.
Plaintiffs are in favor of the Southern District of Illinois because of its central location and because a large number of Pradaxa lawsuits are already in progress there.
Contact a Pradaxa Attorney
The number of Pradaxa lawsuits on the books is steadily growing as more Americans suffer uncontrolled bleeding after taking this potentially dangerous drug. If you or someone you love has experienced injury or death as a result of Pradaxa bleeding, you are legally entitled to compensation in a pharmaceutical product liability lawsuit. Contact an experienced personal injury lawyer today for a free legal consultation.